Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Huang Q, Zeng J, Yan J. COVID-19 mRNA vaccines. J Genet Genomics 2021;48:107-114. [PMID: 34006471 PMCID: PMC7959685 DOI: 10.1016/j.jgg.2021.02.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 01/31/2021] [Accepted: 02/01/2021] [Indexed: 01/08/2023]

For:	Huang Q, Zeng J, Yan J. COVID-19 mRNA vaccines. J Genet Genomics 2021;48:107-114. [PMID: 34006471 PMCID: PMC7959685 DOI: 10.1016/j.jgg.2021.02.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 01/31/2021] [Accepted: 02/01/2021] [Indexed: 01/08/2023]

Number

Cited by Other Article(s)

Xie Z, Lin YC, Steichen JM, Ozorowski G, Kratochvil S, Ray R, Torres JL, Liguori A, Kalyuzhniy O, Wang X, Warner JE, Weldon SR, Dale GA, Kirsch KH, Nair U, Baboo S, Georgeson E, Adachi Y, Kubitz M, Jackson AM, Richey ST, Volk RM, Lee JH, Diedrich JK, Prum T, Falcone S, Himansu S, Carfi A, Yates JR, Paulson JC, Sok D, Ward AB, Schief WR, Batista FD. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science 2024;384:eadk0582. [PMID: 38753770 DOI: 10.1126/science.adk0582] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 04/03/2024] [Indexed: 05/18/2024]

Affiliation(s)

Zhenfei Xie The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Ying-Cing Lin The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Jon M Steichen Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA
Gabriel Ozorowski IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
Sven Kratochvil The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Rashmi Ray The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Jonathan L Torres Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
Alessia Liguori Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA
Oleksandr Kalyuzhniy Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA
Xuesong Wang The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
John E Warner The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Stephanie R Weldon The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Gordon A Dale The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Kathrin H Kirsch The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Usha Nair The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Sabyasachi Baboo Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
Erik Georgeson Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA
Yumiko Adachi Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA
Michael Kubitz Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA
Abigail M Jackson Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
Sara T Richey Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
Reid M Volk Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
Jeong Hyun Lee Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
Jolene K Diedrich Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
Thavaleak Prum The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA
Samantha Falcone Moderna Inc., Cambridge, MA 02139, USA
Sunny Himansu Moderna Inc., Cambridge, MA 02139, USA
Andrea Carfi Moderna Inc., Cambridge, MA 02139, USA
John R Yates Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
James C Paulson Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
Devin Sok Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA
Andrew B Ward IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
William R Schief The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA Moderna Inc., Cambridge, MA 02139, USA
Facundo D Batista The Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Collapse

Zhu Y, Ma J, Shen R, Lin J, Li S, Lu X, Stelzel JL, Kong J, Cheng L, Vuong I, Yao ZC, Wei C, Korinetz NM, Toh WH, Choy J, Reynolds RA, Shears MJ, Cho WJ, Livingston NK, Howard GP, Hu Y, Tzeng SY, Zack DJ, Green JJ, Zheng L, Doloff JC, Schneck JP, Reddy SK, Murphy SC, Mao HQ. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity. Nat Biomed Eng 2024;8:544-560. [PMID: 38082180 PMCID: PMC11162325 DOI: 10.1038/s41551-023-01131-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Accepted: 10/15/2023] [Indexed: 06/09/2024]

Affiliation(s)

Yining Zhu Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Jingyao Ma Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA
Ruochen Shen Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Jinghan Lin Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Shuyi Li Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Xiaoya Lu Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA
Jessica L Stelzel Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Jiayuan Kong Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA
Leonardo Cheng Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Ivan Vuong Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Zhi-Cheng Yao Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA
Christine Wei Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Nicole M Korinetz Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA
Wu Han Toh Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Computer Science, Johns Hopkins University, Baltimore, MD, USA Department of Biology, Johns Hopkins University, Baltimore, MD, USA
Joseph Choy Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA
Rebekah A Reynolds Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA
Melanie J Shears Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA
Won June Cho Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA
Natalie K Livingston Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Gregory P Howard Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Yizong Hu Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Stephany Y Tzeng Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Donald J Zack Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Jordan J Green Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Lei Zheng Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Joshua C Doloff Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Jonathan P Schneck Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Sashank K Reddy Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Sean C Murphy Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA. Department of Microbiology, University of Washington, Seattle, WA, USA.
Hai-Quan Mao Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA. Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA.

Collapse

Kisakov DN, Kisakova LA, Sharabrin SV, Yakovlev VA, Tigeeva EV, Borgoyakova MB, Starostina EV, Zaikovskaya AV, Rudometov AP, Rudometova NB, Karpenko LI, Ilyichev AA. Delivery of Experimental mRNA Vaccine Encoding the RBD of SARS-CoV-2 by Jet Injection. Bull Exp Biol Med 2024;176:776-780. [PMID: 38896316 DOI: 10.1007/s10517-024-06107-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Indexed: 06/21/2024]

Affiliation(s)

D N Kisakov State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
L A Kisakova State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
S V Sharabrin State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
V A Yakovlev State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
E V Tigeeva State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
M B Borgoyakova State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
E V Starostina State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
A V Zaikovskaya State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
A P Rudometov State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
N B Rudometova State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
L I Karpenko State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
A A Ilyichev State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia

Collapse

Cheng L, Zhu Y, Ma J, Aggarwal A, Toh WH, Shin C, Sangpachatanaruk W, Weng G, Kumar R, Mao HQ. Machine Learning Elucidates Design Features of Plasmid DNA Lipid Nanoparticles for Cell Type-Preferential Transfection. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.12.07.570602. [PMID: 38106206 PMCID: PMC10723465 DOI: 10.1101/2023.12.07.570602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2023]

Dhurbachandra Singh C, Morshed Alom K, Kumar Kannan D, Simander Singh T, Samantaray S, Siddappa Ravi Kumara G, Jun Seo Y. mRNA incorporation of C(5)-halogenated pyrimidine ribonucleotides and induced high expression of corresponding protein for the development of mRNA vaccine. Bioorg Chem 2023;141:106897. [PMID: 37793265 DOI: 10.1016/j.bioorg.2023.106897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 09/25/2023] [Accepted: 09/27/2023] [Indexed: 10/06/2023]

Joshi D, Nyhoff LE, Zarnitsyna VI, Moreno A, Manning K, Linderman S, Burrell AR, Stephens K, Norwood C, Mantus G, Ahmed R, Anderson EJ, Staat MA, Suthar MS, Wrammert J. Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults. iScience 2023;26:107967. [PMID: 37822504 PMCID: PMC10562792 DOI: 10.1016/j.isci.2023.107967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 08/25/2023] [Accepted: 09/15/2023] [Indexed: 10/13/2023] Open

Affiliation(s)

Devyani Joshi Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA
Lindsay E. Nyhoff Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA
Veronika I. Zarnitsyna Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA
Alberto Moreno Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Emory National Primate Research Center, Atlanta, GA, USA Department of Medicine, Emory University, School of Medicine, Atlanta, GA, USA
Kelly Manning Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Emory National Primate Research Center, Atlanta, GA, USA
Susanne Linderman Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA
Allison R. Burrell Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA Department of Environmental and Public Health Sciences, Division of Epidemiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Kathy Stephens Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA
Carson Norwood Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA
Grace Mantus Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA
Rafi Ahmed Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA
Evan J. Anderson Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA Department of Medicine, Emory University, School of Medicine, Atlanta, GA, USA
Mary A. Staat Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Mehul S. Suthar Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA Emory National Primate Research Center, Atlanta, GA, USA
Jens Wrammert Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA Centers for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Emory University Department of Pediatrics Department of Medicine, Atlanta, GA, USA

Collapse

Yu MZ, Wang NN, Zhu JQ, Lin YX. The clinical progress and challenges of mRNA vaccines. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2023;15:e1894. [PMID: 37096256 DOI: 10.1002/wnan.1894] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 03/14/2023] [Accepted: 03/20/2023] [Indexed: 04/26/2023]

Cai S, Chang C, Zhang X, Qiao W. Comparative analysis of the effectiveness difference of SARS-COV-2 mRNA vaccine in different populations in the real world: A review. Medicine (Baltimore) 2023;102:e34805. [PMID: 37653835 PMCID: PMC10470718 DOI: 10.1097/md.0000000000034805] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 07/25/2023] [Accepted: 07/27/2023] [Indexed: 09/02/2023] Open

Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, She Q, Tan J, Lou C, Liao Z, Li X. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med 2023;13:e1384. [PMID: 37612832 PMCID: PMC10447885 DOI: 10.1002/ctm2.1384] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 08/10/2023] [Accepted: 08/14/2023] [Indexed: 08/25/2023] Open

Wei H, Rong Z, Liu L, Sang Y, Yang J, Wang S. Streamlined and on-demand preparation of mRNA products on a universal integrated platform. MICROSYSTEMS & NANOENGINEERING 2023;9:97. [PMID: 37492616 PMCID: PMC10363538 DOI: 10.1038/s41378-023-00538-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 03/28/2023] [Accepted: 04/07/2023] [Indexed: 07/27/2023]

Xu W, Ren W, Wu T, Wang Q, Luo M, Yi Y, Li J. Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2023;11:1118. [PMID: 37376508 DOI: 10.3390/vaccines11061118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Revised: 06/13/2023] [Accepted: 06/14/2023] [Indexed: 06/29/2023] Open

Li M, Wang Y, Wu P, Zhang S, Gong Z, Liao Q, Guo C, Wang F, Li Y, Zeng Z, Yan Q, Xiong W. Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy. Cancer Lett 2023;563:216190. [PMID: 37062328 DOI: 10.1016/j.canlet.2023.216190] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 04/04/2023] [Accepted: 04/13/2023] [Indexed: 04/18/2023]

Affiliation(s)

Mohan Li NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China; Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, China
Yian Wang Key Laboratory of Translational Cancer Stem Cell Research, Department of Pathophysiology, Hunan Normal University School of Medicine, Changsha, Hunan, China
Pan Wu Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China
Shanshan Zhang Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, China
Zhaojian Gong Department of Oral and Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China
Qianjin Liao NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China
Can Guo Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China
Fuyan Wang Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China
Yong Li Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China
Zhaoyang Zeng NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China
Qijia Yan Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, China.
Wei Xiong NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China.

Collapse

Joshi D, Nyhoff LE, Zarnitsyna VI, Moreno A, Manning K, Linderman S, Burrell AR, Stephens K, Norwood C, Mantus G, Ahmed R, Anderson EJ, Staat MA, Suthar MS, Wrammert J. Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2023:2023.04.10.23288360. [PMID: 37090559 PMCID: PMC10120804 DOI: 10.1101/2023.04.10.23288360] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/25/2023]

Kisakova LA, Apartsin EK, Nizolenko LF, Karpenko LI. Dendrimer-Mediated Delivery of DNA and RNA Vaccines. Pharmaceutics 2023;15:pharmaceutics15041106. [PMID: 37111593 PMCID: PMC10145063 DOI: 10.3390/pharmaceutics15041106] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/27/2023] [Accepted: 03/28/2023] [Indexed: 04/03/2023] Open

Lee DY, Kang DY, Kim E, Lee SJ, Baek JH, Lee JS, Park MY, Im JH. Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers. Medicine (Baltimore) 2023;102:e33236. [PMID: 36930126 PMCID: PMC10018524 DOI: 10.1097/md.0000000000033236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Accepted: 02/17/2023] [Indexed: 03/18/2023] Open

Abstract

Due to the urgency of controlling the coronavirus disease 2019 pandemic, coronavirus disease 2019 messenger ribonucleic acid (mRNA) vaccines have been expeditiously approved and introduced in several countries without sufficient evaluation for adverse events. We analyzed adverse events among Korean healthcare workers who received all 3 doses of the BNT162b2 mRNA vaccine. This survey was conducted among hospital workers of Inha University Hospital who had received the BNT162b2 mRNA vaccine for their first, second, third rounds, and using a diary card. The surveyed adverse events included local (redness, edema, and injection site pain) and systemic (fever, fatigue, headache, chill, myalgia, arthralgia, vomiting, diarrhea, pruritis, and urticaria) side effects and were divided into 5 grades (Grade 0 = none - Grade 4 = critical). Based on adverse events reported at least once after any of the 3 doses, the most common systemic adverse reactions were chills and headache (respectively, 62.6%, 62.4%), followed by myalgia (55.3%), arthralgia (53.4%), fatigue (51.6%), pruritus (38.1%), and fever (36.5%). The frequency and duration of adverse events were significantly greater in women (P < .05) than men. Except for redness, pruritus, urticaria, and most adverse reactions had a higher rate of occurrence after the third dose in subjects who also had reactions with the second dose. However, grade 4 adverse events did occur with the third dose in some patients, even if there were no side effects with the first and second doses. Adverse events experienced with the first and second doses of the BNT162b2 mRNA vaccine in Korean healthcare workers increased the incidence of adverse events at the time of the third dose. On the other hand, grade 4 adverse events could still occur with the third dose even though there were no side effects with the first and second doses.

Collapse

Mirtaleb MS, Falak R, Heshmatnia J, Bakhshandeh B, Taheri RA, Soleimanjahi H, Zolfaghari Emameh R. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations. Int Immunopharmacol 2023;117:109934. [PMID: 36867924 PMCID: PMC9968612 DOI: 10.1016/j.intimp.2023.109934] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 02/09/2023] [Accepted: 02/21/2023] [Indexed: 03/01/2023]

Zhang YQ, Guo RR, Chen YH, Li TC, Du WZ, Xiang RW, Guan JB, Li YP, Huang YY, Yu ZQ, Cai Y, Zhang P, Ling GX. Ionizable drug delivery systems for efficient and selective gene therapy. Mil Med Res 2023;10:9. [PMID: 36843103 PMCID: PMC9968649 DOI: 10.1186/s40779-023-00445-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 02/01/2023] [Indexed: 02/28/2023] Open

Meurisse M, Catteau L, van Loenhout JAF, Braeye T, De Mot L, Serrien B, Blot K, Cauët E, Van Oyen H, Cuypers L, Robert A, Van Goethem N. Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium. Vaccines (Basel) 2023;11:vaccines11020378. [PMID: 36851257 PMCID: PMC9961733 DOI: 10.3390/vaccines11020378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 02/01/2023] [Accepted: 02/02/2023] [Indexed: 02/10/2023] Open

Mao S, Li S, Zhang Y, Long L, Peng J, Cao Y, Mao JZ, Qi X, Xin Q, San G, Ding J, Jiang J, Bai X, Wang Q, Xu P, Xia H, Lu L, Xie L, Kong D, Zhu S, Xu W. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. NANO TODAY 2023;48:101730. [PMID: 36570700 PMCID: PMC9767897 DOI: 10.1016/j.nantod.2022.101730] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 12/05/2022] [Accepted: 12/13/2022] [Indexed: 05/14/2023]

Affiliation(s)

Shanhong Mao School of Biomedical Engineering, Capital Medical University, Beijing 100069, China School of Light Industry, Beijing Technology and Business University, Beijing 100048, China
Shiyou Li Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Yuxin Zhang Beijing QS Medical Technology Co.,Ltd., Beijing 100176, China
Luoxin Long School of Biomedical Engineering, Capital Medical University, Beijing 100069, China
Junfeng Peng Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Yuanyan Cao School of Biomedical Engineering, Capital Medical University, Beijing 100069, China
Jessica Z Mao School of Veterinary Medicine & Biomedical Sciences, Texas A&M, College Station, TX 77843, USA
Xin Qi Beijing QS Medical Technology Co.,Ltd., Beijing 100176, China
Qi Xin Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Guoliang San Beijing QS Medical Technology Co.,Ltd., Beijing 100176, China
Jing Ding Beijing QS Medical Technology Co.,Ltd., Beijing 100176, China
Jun Jiang Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Xuejiao Bai Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Qianting Wang Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Pengfei Xu Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Huan Xia Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Lijun Lu Tricision Biotherapeutic Inc, Beijing 100176, Zhuhai 519040, China
Liangzhi Xie Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China
Desheng Kong Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China
Shuangli Zhu National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
Wenbo Xu National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

Collapse

Satterfield BA, Mire CE, Geisbert TW. Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection. Methods Mol Biol 2023;2682:1-22. [PMID: 37610570 DOI: 10.1007/978-1-0716-3283-3_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/24/2023]

Klotz K, Radwan Y, Chakrabarti K. Dissecting Functional Biological Interactions Using Modular RNA Nanoparticles. Molecules 2022;28:molecules28010228. [PMID: 36615420 PMCID: PMC9821959 DOI: 10.3390/molecules28010228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 12/22/2022] [Accepted: 12/25/2022] [Indexed: 12/29/2022] Open

Yin S, Mei S, Li Z, Xu Z, Wu Y, Chen X, Liu D, Niu MM, Li J. Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75. Front Pharmacol 2022;13:1037993. [PMID: 36408220 PMCID: PMC9666779 DOI: 10.3389/fphar.2022.1037993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 10/21/2022] [Indexed: 11/05/2022] Open

Huang S, Zhu Y, Zhang L, Zhang Z. Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2022;34:e2107946. [PMID: 34914144 DOI: 10.1002/adma.202107946] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 12/11/2021] [Indexed: 06/14/2023]

Shi R, Zeng J, Xu L, Wang F, Duan X, Wang Y, Wu Z, Yu D, Huang Q, Yao YG, Yan J. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. EBioMedicine 2022;85:104297. [PMID: 36206623 PMCID: PMC9530591 DOI: 10.1016/j.ebiom.2022.104297] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 09/20/2022] [Accepted: 09/20/2022] [Indexed: 11/07/2022] Open

Affiliation(s)

Rui Shi CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
Jiawei Zeng CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
Ling Xu Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China,Kunming National High-level Biosafety Research Center for Non-Human Primates, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China
Fengze Wang CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
Xiaomin Duan CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
Yue Wang CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China
Zheng Wu CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,Institute of Physical Science and Information, Anhui University, Hefei, 230039, China
Dandan Yu Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China,Kunming National High-level Biosafety Research Center for Non-Human Primates, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China
Qingrui Huang CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,Corresponding authors.
Yong-Gang Yao Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China,Kunming National High-level Biosafety Research Center for Non-Human Primates, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China,National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650107, China,Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan 650204, China,Corresponding authors.
Jinghua Yan CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China,University of Chinese Academy of Sciences, Beijing 100049, China,Corresponding authors.

Collapse

ÇEVİK B. Association of COVID-19 vaccine with lymph node reactivity: an ultrasound-based study. JOURNAL OF HEALTH SCIENCES AND MEDICINE 2022. [DOI: 10.32322/jhsm.1123597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open

Huang Q, Han X, Yan J. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Emerg Microbes Infect 2022;11:2412-2422. [PMID: 36106670 PMCID: PMC9553185 DOI: 10.1080/22221751.2022.2125348] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]

Nurpeisova A, Khairullin B, Abitaev R, Shorayeva K, Jekebekov K, Kalimolda E, Kerimbayev A, Akylbayeva K, Abay Z, Myrzakhmetova B, Nakhanov A, Absatova Z, Nurabayev S, Orynbayev M, Assanzhanova N, Abeuov K, Kutumbetov L, Kassenov M, Abduraimov Y, Zakarya K. Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19. Hum Vaccin Immunother 2022;18:2087412. [PMID: 35960911 DOI: 10.1080/21645515.2022.2087412] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open

Affiliation(s)

Ainur Nurpeisova Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Berik Khairullin Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Ruslan Abitaev Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Kamshat Shorayeva Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Kuanish Jekebekov Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Elina Kalimolda Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Aslan Kerimbayev Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Karligash Akylbayeva Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Zhandos Abay Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Balzhan Myrzakhmetova Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Aziz Nakhanov Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Zharkinay Absatova Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Sergazy Nurabayev Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Mukhit Orynbayev Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Nurika Assanzhanova Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Khairulla Abeuov Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Lespek Kutumbetov Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Markhabat Kassenov Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Yergaly Abduraimov Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan
Kunsulu Zakarya Research Institute for Biological Safety Problems (RIBSP), Guardeyskiy, Kazakhstan

Collapse

Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. Polymers (Basel) 2022;14:polym14163263. [PMID: 36015519 PMCID: PMC9414445 DOI: 10.3390/polym14163263] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/05/2022] [Accepted: 08/06/2022] [Indexed: 12/12/2022] Open

Messerian KO, Zverev A, Kramarczyk JF, Zydney AL. Pressure-dependent fouling behavior during sterile filtration of mRNA-containing lipid nanoparticles. Biotechnol Bioeng 2022;119:3221-3229. [PMID: 35906785 DOI: 10.1002/bit.28200] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 07/25/2022] [Accepted: 07/26/2022] [Indexed: 11/11/2022]

Seibert D, Wysocki K. The genomics of COVID. J Am Assoc Nurse Pract 2022;34:872-875. [PMID: 35796108 DOI: 10.1097/jxx.0000000000000727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 03/30/2022] [Indexed: 11/26/2022]

Hameed SA, Paul S, Dellosa GKY, Jaraquemada D, Bello MB. Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies. NPJ Vaccines 2022;7:71. [PMID: 35764661 PMCID: PMC9239993 DOI: 10.1038/s41541-022-00485-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Accepted: 05/13/2022] [Indexed: 02/07/2023] Open

Zhang Y, Liu Q, Zhang X, Huang H, Tang S, Chai Y, Xu Z, Li M, Chen X, Liu J, Yang C. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J Nanobiotechnology 2022;20:279. [PMID: 35701788 PMCID: PMC9194774 DOI: 10.1186/s12951-022-01472-z] [Citation(s) in RCA: 109] [Impact Index Per Article: 54.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 05/19/2022] [Indexed: 02/07/2023] Open

Affiliation(s)

Ying Zhang Central Laboratory of Longgang District People's Hospital of Shenzhen & The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen, 518172, China Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Qiqi Liu Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Xinmeng Zhang Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Haoqiang Huang Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Shiqi Tang Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Yujuan Chai Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Zhourui Xu Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Meirong Li Central Laboratory of Longgang District People's Hospital of Shenzhen & The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen, 518172, China Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Xin Chen Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
Jia Liu Central Laboratory of Longgang District People's Hospital of Shenzhen & The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen, 518172, China.
Chengbin Yang Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China.

Collapse

Bignon E, Marazzi M, Grandemange S, Monari A. Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer. Chem Sci 2022;13:6098-6105. [PMID: 35685814 PMCID: PMC9132136 DOI: 10.1039/d2sc00108j] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 04/29/2022] [Indexed: 12/21/2022] Open

Garduño-González KA, Peña-Benavides SA, Araújo RG, Castillo-Zacarías C, Melchor-Martínez EM, Oyervides-Muñoz MA, Sosa-Hernández JE, Purton S, Iqbal HM, Parra-Saldívar R. Current challenges for modern vaccines and perspectives for novel treatment alternatives. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103222] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]

Belete TM. The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review. Open Microbiol J 2022. [DOI: 10.2174/18742858-v16-e2201240] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open

Notarte KI, Guerrero-Arguero I, Velasco JV, Ver AT, de Oliveira MHS, Catahay JA, Khan SR, Pastrana A, Juszczyk G, Torrelles JB, Lippi G, Martinez-Sobrido L, Henry BM. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J Med Virol 2022;94:2939-2961. [PMID: 35229324 PMCID: PMC9088566 DOI: 10.1002/jmv.27688] [Citation(s) in RCA: 74] [Impact Index Per Article: 37.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/16/2022] [Accepted: 02/27/2022] [Indexed: 11/11/2022]

Bellos I, Karageorgiou V, Viskin D. Myocarditis following mRNA Covid-19 vaccination: a pooled analysis. Vaccine 2022;40:1768-1774. [PMID: 35153093 PMCID: PMC8818354 DOI: 10.1016/j.vaccine.2022.02.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 01/22/2022] [Accepted: 02/02/2022] [Indexed: 12/15/2022]

Wang AYL. Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. Cell Transplant 2022;31:9636897221090259. [PMID: 35438579 PMCID: PMC9021518 DOI: 10.1177/09636897221090259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open

Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans. IMMUNO 2021. [DOI: 10.3390/immuno1040032] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open

Mu X, Hur S. Immunogenicity of In Vitro-Transcribed RNA. Acc Chem Res 2021;54:4012-4023. [PMID: 34677064 PMCID: PMC9127547 DOI: 10.1021/acs.accounts.1c00521] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]

Abstract

In vitro-transcribed RNAs are emerging as new biologics for therapeutic innovation, as exemplified by their application recently in SARS-CoV-2 vaccinations. RNAs prepared by in vitro transcription (IVT) allow transient expression of proteins of interest, conferring safety over DNA- or virus-mediated gene delivery systems. However, in vitro-transcribed RNAs should be used with caution because of their immunogenicity, which is in part triggered by double-stranded RNA (dsRNA) byproducts during IVT. Cellular innate immune response to dsRNA byproducts can lead to undesirable consequences, including suppression of protein synthesis and cell death, which in turn can detrimentally impact the efficacy of mRNA therapy. Thus, it is critical to understand the nature of IVT byproducts and the mechanisms by which they trigger innate immune responses.Our lab has been investigating the mechanisms by which the innate immune system discriminates between "self" and "nonself" RNA, with the focus on the cytoplasmic dsRNA receptors retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated 5 (MDA5). We have biochemically and structurally characterized critical events involving RNA discrimination and signal transduction by RIG-I or MDA5. We have used in vitro-transcribed RNAs as tools to investigate RNA specificity of RIG-I and MDA5, which required optimization of the IVT reaction and purification processes to eliminate the effect of IVT byproducts. In this Account, we summarize our current understanding of RIG-I and MDA5 and IVT reactions and propose future directions for improving IVT as a method to generate both research tools and therapeutics. Other critical proteins in cellular innate immune response to dsRNAs are also discussed. We arrange the contents in the following order: (i) innate immunity sensors for nonself RNA, including the RIG-I-like receptors (RLRs) in the cytosol and the toll-like receptors (TLRs) in the endosome, as well as cytoplasmic dsRNA-responding proteins, including protein kinase R (PKR) and 2',5'-oligoadenylate synthetases (OASes), illustrating the feature of protein-RNA binding and its consequences; (ii) the immunogenicity of IVT byproducts, specifically the generation of dsRNA molecules during IVT; and (iii) methods to reduce IVT RNA immunogenicity, including optimizations of RNA polymerases, reagents, and experimental conditions during IVT and subsequent purification.

Collapse

Magro C, Crowson AN, Franks L, Schaffer PR, Whelan P, Nuovo G. The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. Clin Dermatol 2021;39:966-984. [PMID: 34920834 PMCID: PMC8310467 DOI: 10.1016/j.clindermatol.2021.07.011] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]

Abstract

A total of 22 patients who had developed an adverse cutaneous reaction to the Moderna or Pfizer vaccine underwent biopsies. Each patient was assessed light microscopically, and, in select biopsies, spike glycoprotein and cytokine assessment were also conducted. The patients developed self-limited cutaneous reactions often described clinically as urticarial or eczematous within 1 day to 4 weeks after receiving the first or second dose of the Pfizer or Moderna vaccine. Classic clinical and morphologic depictions of type IV cutaneous hypersensitivity with features of eczematous dermatitis, interface dermatitis, granulomatous inflammation, and/or lymphocytic vasculitic component were observed. Clinical and/or histologic features of perniosis, pityriasis rosea, pityriasis rubra pilaris, and guttate psoriasis were seen in select cases. In 2 cases the dominant picture was urticarial vasculitis, possibly reflective of an Arthus type III immune complex action. The biopsy specimens of normal skin post vaccine and of skin affected by the post-vaccine eruption showed rare deep microvessels positive for spike glycoprotein with no complement deposition contrasting with greater vascular deposition of spike protein and complement in skin biopsies from patients experiencing severe coronavirus disease 2019 (COVID-19). It is concluded that self-limited hypersensitivity reactions to the vaccine occur possibly owing to a substance found in the vaccine vehicle (eg, polyethylene glycol). An immune response that is directed against human-manufactured spike has to be considered because some of the reactions clinically and or histologically closely resemble mild COVID-19. Finally, vaccine-associated immune enhancement largely attributable to the adjuvant properties of the vaccine may unmask certain inflammatory milieus operational in psoriasis, atopic dermatitis, and subclinical hypersensitivity.

Collapse

Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. Biologics 2021. [DOI: 10.3390/biologics1030020] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]

Marchand A, Roulland I, Semence F, Beck O, Ericsson M. Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2. Life (Basel) 2021;11:life11111125. [PMID: 34833001 PMCID: PMC8620034 DOI: 10.3390/life11111125] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 10/12/2021] [Accepted: 10/15/2021] [Indexed: 12/23/2022] Open

Abstract

To combat the COVID-19 pandemic, vaccines against SARS-CoV-2 are now given to protect populations worldwide. The level of neutralizing antibodies following the vaccination will evolve with time and vary between individuals. Immunoassays quantifying immunoglobulins against the viral spike (S) protein in serum/plasma have been developed, but the need for venous blood samples could limit the frequency and scale of control in populations. The use of a quantitative dried blood spot (DBS) that can be self-collected would simplify this monitoring. The objective of this study was to determine whether a quantitative DBS device (Capitainer qDBS 10 µL) could be used in combination with an Elecsys anti-SARS-CoV-2 S immunoassay from Roche to follow the development and persistence of anti-S antibodies. This objective was carried out through two clinical studies. The first study investigated 14 volunteers who received two doses of the Comirnaty (Pfizer) vaccine. The levels of anti-S antibodies and the progression over time post-vaccination were studied for three months. The level of produced antibodies varied between subjects, but a similar trend was observed. The anti-S antibodies were highly stimulated by the second dose (×100) and peaked two weeks later. The antibody levels subsequently decreased and three months later were down to 65%. DBS proved to be sufficiently sensitive for use in evaluating the immune status against SARS-CoV-2 over a prolonged time. The second cohort was composed of 200 random patients from a clinical chemistry department in Stockholm. In this cohort, we had no information on previous COVID-19 infections or vaccination. Nevertheless, 87% of the subjects had anti-S immunoglobulins over 0.8 U/mL, and the bias between plasma and DBS proved to be variable, as was also seen in the first vaccination study.

Collapse

Zieneldien T, Kim J, Cao J, Cao C. COVID-19 Vaccines: Current Conditions and Future Prospects. BIOLOGY 2021;10:biology10100960. [PMID: 34681059 PMCID: PMC8533517 DOI: 10.3390/biology10100960] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 09/17/2021] [Accepted: 09/22/2021] [Indexed: 02/06/2023]

Uddin MN, Roni MA. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. Vaccines (Basel) 2021;9:1033. [PMID: 34579270 PMCID: PMC8473088 DOI: 10.3390/vaccines9091033] [Citation(s) in RCA: 141] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 09/08/2021] [Accepted: 09/13/2021] [Indexed: 01/14/2023] Open

Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines (Basel) 2021;9:vaccines9080848. [PMID: 34451973 PMCID: PMC8402319 DOI: 10.3390/vaccines9080848] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 07/28/2021] [Accepted: 07/30/2021] [Indexed: 02/06/2023] Open

Tardiolo G, Brianti P, Sapienza D, dell’Utri P, Dio VD, Rao G, Calabrò RS. Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization. Med Sci (Basel) 2021;9:53. [PMID: 34449681 PMCID: PMC8395838 DOI: 10.3390/medsci9030053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 07/27/2021] [Accepted: 07/28/2021] [Indexed: 01/08/2023] Open

Gil Martínez V, Avedillo Salas A, Santander Ballestín S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceuticals (Basel) 2021;14:736. [PMID: 34451833 PMCID: PMC8398077 DOI: 10.3390/ph14080736] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 07/20/2021] [Accepted: 07/23/2021] [Indexed: 12/12/2022] Open

A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Curr Med Sci 2021;41:1037-1051. [PMID: 34241776 PMCID: PMC8267225 DOI: 10.1007/s11596-021-2395-1] [Citation(s) in RCA: 118] [Impact Index Per Article: 39.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 06/25/2021] [Indexed: 02/08/2023]